Skip to main content
Erschienen in: Journal of Neurology 9/2015

01.09.2015 | Original Communication

Quality of life in patients with progressive supranuclear palsy: one-year follow-up

verfasst von: Tatjana Pekmezović, Milica Ječmenica-Lukić, Igor Petrović, Vladana Špica, Aleksandra Tomić, Vladimir S. Kostić

Erschienen in: Journal of Neurology | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

The aim of this prospective cohort study that included 46 patients with progressive supranuclear palsy (PSP) was to estimate which demographic and clinical factors were the main contributors to the health-related quality of life (HRQoL) and how did the HRQoL change over a follow-up period of 1 year in these patients. The hierarchical regression analyses showed that the final models demonstrated that gender, included clinical variables and psychiatric/neuropsychological scales, accounted for 68 % of the variance in the Physical Composite Score and 73 % of the variance of the Mental Composite Score of the 36-item Short Form Health Survey (SF-36). Among variables in both final models, only the score of the Apathy Evaluation Scale showed statistically significant negative predictive value (p < 0.05). Changes in the HRQoL scores were assessed in 28 PSP patients who completed 1-year follow-up period after the baseline examination. Statistically significant decline in the HRQoL was detected for the following scales of the SF-36: physical functioning, vitality, social functioning, and role emotional, as well as in both composite scores (Physical Composite Score and Mental Composite Score). The analyses of magnitude of changes in the HRQoL during 1-year follow-up period showed large effect size (≥0.80) for total scores, as well as for the physical functioning, vitality, and social functioning. In conclusion, despite certain limitations, our study provided some new insights into potential predictors of the HRQoL and its longitudinal changes in patients with PSP.
Literatur
1.
Zurück zum Zitat Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1–9CrossRefPubMed Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1–9CrossRefPubMed
2.
Zurück zum Zitat Schrag A, Selai C, Quinn N, Lees A, Litvan I, Lang A, Poon Y, Bower J, Burn D, Hobart J (2006) Measuring quality of life in PSP. The PSP-QoL. Neurology 67(1):39–44CrossRefPubMed Schrag A, Selai C, Quinn N, Lees A, Litvan I, Lang A, Poon Y, Bower J, Burn D, Hobart J (2006) Measuring quality of life in PSP. The PSP-QoL. Neurology 67(1):39–44CrossRefPubMed
3.
Zurück zum Zitat Brooks DJ (2002) Diagnosis and management of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 72(Suppl. 1):10–16 Brooks DJ (2002) Diagnosis and management of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 72(Suppl. 1):10–16
4.
Zurück zum Zitat Wenning GK, Litvan I, Tolosa E (2011) Milestones in atypical and secondary parkinsonisms. Mov Disord 26(6):1083–1095CrossRefPubMed Wenning GK, Litvan I, Tolosa E (2011) Milestones in atypical and secondary parkinsonisms. Mov Disord 26(6):1083–1095CrossRefPubMed
5.
Zurück zum Zitat Osaki Y, Ben-Shlomo Y, Lees AJ, Daniel SE, Colosimo C, Wenning G, Quinn N (2004) Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 19(2):181–189CrossRefPubMed Osaki Y, Ben-Shlomo Y, Lees AJ, Daniel SE, Colosimo C, Wenning G, Quinn N (2004) Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 19(2):181–189CrossRefPubMed
6.
Zurück zum Zitat Higginson IJ, Gao W, Saleem TZ, Chaudhuri KR, Burman R, Mc Crone P, Leigh PN (2012) Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS One 7(11):e46327PubMedCentralCrossRefPubMed Higginson IJ, Gao W, Saleem TZ, Chaudhuri KR, Burman R, Mc Crone P, Leigh PN (2012) Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS One 7(11):e46327PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Calvert M, Pall H, Hoppitt T, Eaton B, Savill E, Sackley C (2013) Health-related quality of life and supportive care in patients with rare long-term neurological conditions. Qual Life Res 22(6):1231–1238CrossRefPubMed Calvert M, Pall H, Hoppitt T, Eaton B, Savill E, Sackley C (2013) Health-related quality of life and supportive care in patients with rare long-term neurological conditions. Qual Life Res 22(6):1231–1238CrossRefPubMed
8.
Zurück zum Zitat Schrag A, Selai C, Davis J, Lees AJ, Jahanshahi M, Quinn N (2003) Health-related quality of life in patients with progressive supranuclear palsy. Mov Disord 18(12):1464–1469CrossRefPubMed Schrag A, Selai C, Davis J, Lees AJ, Jahanshahi M, Quinn N (2003) Health-related quality of life in patients with progressive supranuclear palsy. Mov Disord 18(12):1464–1469CrossRefPubMed
9.
Zurück zum Zitat Schrag A, Selai C, Quinn N, Hobart J (2005) Measuring health-related quality of life in patients with progressive supranuclear palsy. Neurocase 11(4):246–249CrossRefPubMed Schrag A, Selai C, Quinn N, Hobart J (2005) Measuring health-related quality of life in patients with progressive supranuclear palsy. Neurocase 11(4):246–249CrossRefPubMed
10.
Zurück zum Zitat Schrag A, Sheikh S, Quinn NP, Lees AJ, Selai C, Mathias C, Litvan I, Lang AE, Bower JH, Burn DJ, Low P, Jahanshahi M (2010) A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 25(8):1077–1081CrossRefPubMed Schrag A, Sheikh S, Quinn NP, Lees AJ, Selai C, Mathias C, Litvan I, Lang AE, Bower JH, Burn DJ, Low P, Jahanshahi M (2010) A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 25(8):1077–1081CrossRefPubMed
11.
Zurück zum Zitat Winter Y, Spottke AE, Stamelou M, Cabanel N, Eggert K, Höglinger GU, Sixel-Doering F, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R (2011) Health-related quality of life in multiple system atrophy and progressive supranuclear palsy. Neurodegener Dis 8(6):438–446CrossRefPubMed Winter Y, Spottke AE, Stamelou M, Cabanel N, Eggert K, Höglinger GU, Sixel-Doering F, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R (2011) Health-related quality of life in multiple system atrophy and progressive supranuclear palsy. Neurodegener Dis 8(6):438–446CrossRefPubMed
12.
Zurück zum Zitat Winter Y, Stamelou M, Cabanel N, Sixel-Döring F, Eggert K, Höglinger GU, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R, Spottke AE (2011) Cost-of-illness in multiple system atrophy and progressive supranuclear palsy. J Neurol 258(10):1827–1834CrossRefPubMed Winter Y, Stamelou M, Cabanel N, Sixel-Döring F, Eggert K, Höglinger GU, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R, Spottke AE (2011) Cost-of-illness in multiple system atrophy and progressive supranuclear palsy. J Neurol 258(10):1827–1834CrossRefPubMed
13.
Zurück zum Zitat Jecmenica-Lukic M, Petrovic IN, Pekmezovic T, Kostic VS (2014) Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. J Neurol 261(8):1575–1583CrossRefPubMed Jecmenica-Lukic M, Petrovic IN, Pekmezovic T, Kostic VS (2014) Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. J Neurol 261(8):1575–1583CrossRefPubMed
14.
Zurück zum Zitat Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442CrossRefPubMed Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442CrossRefPubMed
15.
Zurück zum Zitat Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130(Pt6):1552–1565CrossRefPubMed Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130(Pt6):1552–1565CrossRefPubMed
16.
Zurück zum Zitat Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6(4):278–286CrossRefPubMed Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6(4):278–286CrossRefPubMed
17.
18.
Zurück zum Zitat Marin RS, Biedrzycki RC, Firinciogullari S (1991) Reliability and validity of the Apathy Evaluation Scale. Psychiat Res 38(2):143–162CrossRef Marin RS, Biedrzycki RC, Firinciogullari S (1991) Reliability and validity of the Apathy Evaluation Scale. Psychiat Res 38(2):143–162CrossRef
19.
Zurück zum Zitat Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12):2308–2314CrossRefPubMed Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12):2308–2314CrossRefPubMed
20.
Zurück zum Zitat Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR (2006) The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21(11):1078–1085CrossRefPubMed Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR (2006) The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21(11):1078–1085CrossRefPubMed
21.
Zurück zum Zitat Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55(11):1621–1626CrossRefPubMed Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55(11):1621–1626CrossRefPubMed
23.
Zurück zum Zitat Ware JE, Snow KK, Kosinski M (1993) The SF-36 health survey manual and interpretation guide. Nimrod Press, Boston Ware JE, Snow KK, Kosinski M (1993) The SF-36 health survey manual and interpretation guide. Nimrod Press, Boston
24.
Zurück zum Zitat Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Academic Press, New York Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Academic Press, New York
25.
Zurück zum Zitat Gerstenecker A, Duff K, Mast B, Litvan I, ENGENE-PSP Study Group (2013) Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res 210(3):1205–1210CrossRefPubMed Gerstenecker A, Duff K, Mast B, Litvan I, ENGENE-PSP Study Group (2013) Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res 210(3):1205–1210CrossRefPubMed
26.
Zurück zum Zitat Benito-León J, Cubo E, Coronell C, ANIMO Study Group (2012) Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study. Mov Disord 27(2):211–218CrossRefPubMed Benito-León J, Cubo E, Coronell C, ANIMO Study Group (2012) Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study. Mov Disord 27(2):211–218CrossRefPubMed
27.
Zurück zum Zitat Aarsland D, Litvan I, Larsen JP (2001) Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13(1):42–49CrossRefPubMed Aarsland D, Litvan I, Larsen JP (2001) Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13(1):42–49CrossRefPubMed
28.
Zurück zum Zitat Borroni B, Alberici A, Agosti C, Cosseddu M, Padovani A (2009) Pattern of behavioral disturbances in corticobasal degeneration syndrome and progressive supranuclear palsy. Int Psychogeriatr 21(3):463–468CrossRefPubMed Borroni B, Alberici A, Agosti C, Cosseddu M, Padovani A (2009) Pattern of behavioral disturbances in corticobasal degeneration syndrome and progressive supranuclear palsy. Int Psychogeriatr 21(3):463–468CrossRefPubMed
29.
Zurück zum Zitat Varanese S, Perfetti B, Ghilardi MF, Di Rocco A (2011) Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease. PLoS One 6(3):e17846.3CrossRef Varanese S, Perfetti B, Ghilardi MF, Di Rocco A (2011) Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease. PLoS One 6(3):e17846.3CrossRef
30.
Zurück zum Zitat Cordato NJ, Pantelis C, Halliday GM, Velakoulis D, Wood SJ, Stuart GW, Currie J, Soo M, Olivieri G, Broe GA, Morris JG (2002) Frontal atrophy correlates with behavioral changes in progressive supranuclear palsy. Brain 125(Pt4):789–800CrossRefPubMed Cordato NJ, Pantelis C, Halliday GM, Velakoulis D, Wood SJ, Stuart GW, Currie J, Soo M, Olivieri G, Broe GA, Morris JG (2002) Frontal atrophy correlates with behavioral changes in progressive supranuclear palsy. Brain 125(Pt4):789–800CrossRefPubMed
31.
Zurück zum Zitat Agosta F, Galantucci S, Svetel M, Lukić MJ, Copetti M, Davidovic K, Tomić A, Spinelli EG, Kostić VS, Filippi M (2014) Clinical, cognitive, and behavioral correlates of white matter damage in progressive supranuclear palsy. J Neurol 261(5):913–924CrossRefPubMed Agosta F, Galantucci S, Svetel M, Lukić MJ, Copetti M, Davidovic K, Tomić A, Spinelli EG, Kostić VS, Filippi M (2014) Clinical, cognitive, and behavioral correlates of white matter damage in progressive supranuclear palsy. J Neurol 261(5):913–924CrossRefPubMed
32.
Zurück zum Zitat Pedhazur EJ (1997) Multiple regression in behavioral research. Explanation and prediction. Wadsworth Publishing, Orlando Pedhazur EJ (1997) Multiple regression in behavioral research. Explanation and prediction. Wadsworth Publishing, Orlando
33.
Zurück zum Zitat Meissner WG, Foubert-Samier A, Dupouy S, Gerdelat-Mas A, Debs R, Marquant F, De Cock VC, Rascol O, Tison F, Pavy-Le Traon A (2012) Assessment of quality of life with the multiple system atrophy health-related quality of life scale. Mov Disord 27(12):1574–1577CrossRefPubMed Meissner WG, Foubert-Samier A, Dupouy S, Gerdelat-Mas A, Debs R, Marquant F, De Cock VC, Rascol O, Tison F, Pavy-Le Traon A (2012) Assessment of quality of life with the multiple system atrophy health-related quality of life scale. Mov Disord 27(12):1574–1577CrossRefPubMed
34.
Zurück zum Zitat May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW, North American Multiple System Atrophy Study Group (2007) Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord 22(16):2371–2377CrossRefPubMed May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW, North American Multiple System Atrophy Study Group (2007) Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord 22(16):2371–2377CrossRefPubMed
35.
Zurück zum Zitat Köllensperger M, Stampfer-Kountchev M, Seppi K, Geser F, Frick C, Del Sorbo F, Albanese A, Gurevich T, Giladi N, Djaldetti R, Schrag A, Low PA, Mathias CJ, Poewe W, Wenning GK (2007) Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur J Neurol 14(1):66–72CrossRefPubMed Köllensperger M, Stampfer-Kountchev M, Seppi K, Geser F, Frick C, Del Sorbo F, Albanese A, Gurevich T, Giladi N, Djaldetti R, Schrag A, Low PA, Mathias CJ, Poewe W, Wenning GK (2007) Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur J Neurol 14(1):66–72CrossRefPubMed
36.
Zurück zum Zitat Brown CA, Cheng EM, Hays RD, Vassar SD, Vickrey BG (2009) SF-36 includes less Parkinson disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res 18(9):1219–1237PubMedCentralCrossRefPubMed Brown CA, Cheng EM, Hays RD, Vassar SD, Vickrey BG (2009) SF-36 includes less Parkinson disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res 18(9):1219–1237PubMedCentralCrossRefPubMed
Metadaten
Titel
Quality of life in patients with progressive supranuclear palsy: one-year follow-up
verfasst von
Tatjana Pekmezović
Milica Ječmenica-Lukić
Igor Petrović
Vladana Špica
Aleksandra Tomić
Vladimir S. Kostić
Publikationsdatum
01.09.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 9/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7815-3

Weitere Artikel der Ausgabe 9/2015

Journal of Neurology 9/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.